Synergy Pharmaceuticals Inc. (SGYP) EPS Estimated At $-0.19; ENVIROLEACH TECH ORDINARY SHARES CA (EVLLF) SI Increased By 76.9%

February 22, 2018 - By Louis Casey

Analysts expect Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report $-0.19 EPS on March, 1 after the close.They anticipate $0.12 EPS change or 38.71% from last quarter’s $-0.31 EPS. After having $-0.22 EPS previously, Synergy Pharmaceuticals Inc.’s analysts see -13.64% EPS growth. The stock decreased 2.60% or $0.05 during the last trading session, reaching $1.87. About 4.22M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since February 22, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

ENVIROLEACH TECH INC ORDINARY SHARES CA (OTCMKTS:EVLLF) had an increase of 76.9% in short interest. EVLLF’s SI was 58,200 shares in February as released by FINRA. Its up 76.9% from 32,900 shares previously. With 173,800 avg volume, 0 days are for ENVIROLEACH TECH INC ORDINARY SHARES CA (OTCMKTS:EVLLF)’s short sellers to cover EVLLF’s short positions. The stock increased 8.54% or $0.1179 during the last trading session, reaching $1.4979. About shares traded. EnviroLeach Technologies Inc. (OTCMKTS:EVLLF) has 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.




EnviroLeach Technologies Inc. focuses on developing and marketing hydrometallurgy solutions to the mining and e-waste sectors in British Columbia and Alberta, Canada. The company has market cap of $78.18 million.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $461.25 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.41, from 1.49 in 2017Q2. It improved, as 16 investors sold Synergy Pharmaceuticals Inc. shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Credit Suisse Ag has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Edge Wealth Management Limited Liability Corporation has 50 shares. Cornerstone Mgmt Limited Liability invested in 0% or 194,359 shares. Natl Planning holds 0.01% or 10,000 shares. Tower Rech Cap Ltd Liability Co (Trc) holds 0% or 1,632 shares in its portfolio. The Maryland-based Price T Rowe Associate Md has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). 27,595 are owned by Royal National Bank & Trust Of Canada. Moreover, State Of Wisconsin Investment Board has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Moreover, Ameritas Investment Ptnrs has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 19,906 shares. Barclays Public Limited Com holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 29,666 shares. Morgan Stanley accumulated 1.99 million shares. Creative Planning owns 34,205 shares. Fny Managed Accounts Limited Liability Com reported 6,400 shares. Balyasny Asset Mgmt Limited Liability Corp reported 1.38M shares or 0.02% of all its holdings. Prelude Capital Mngmt Limited Co reported 139,704 shares.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 40 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, November 21 with “Buy”. The rating was maintained by H.C. Wainwright on Monday, June 12 with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $1100 target in Wednesday, June 7 report. The company was maintained on Thursday, August 10 by H.C. Wainwright. BTIG Research maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Friday, January 26 with “Buy” rating. The rating was maintained by H.C. Wainwright on Wednesday, October 18 with “Buy”. As per Wednesday, May 31, the company rating was maintained by BTIG Research. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given on Tuesday, August 25 by BTIG Research. As per Monday, September 25, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Thursday, February 1 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.